TD001: a New Potent ADC for Prostate Cancer Expressing PSMA
/in Antibody-Drug Conjugate, Preclinical Research/by MaxPredictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients
/in Drug repurposing, Preclinical Research/by MaxAdvancements in Delivery: Gene Therapy Could Help Prostate Cancer Treatment
/in CRISPR, Delivery, Preclinical Research/by MaxNew Molecule Boosts Vaccine Power Against Cancer and Viruses, In Vivo Study
/in Immunotherapy, Preclinical Research/by MaxAI-Guided Cancer Vaccines Signal a New Era in Personalized Medicine
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxTelomir-1: Innovative Molecule Slows Tumor Growth and Reduces Chemotherapy Toxicity
/in Preclinical Research/by MaxBreaking Resistance: A Dual-Pathway Drug Shows Promise for Advanced Prostate Cancer
/in Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
